Arcturus Therapeutics Ltd, a RNA medicines company, has merged with Alcobra Ltd.  The combined company has net cash of around $50.1 million for use in funding its research and development activities. Those activities will be focused on RNA medicines in therapeutic areas including rare liver diseases, infectious diseases, cystic fibrosis, nonalcoholic steatohepatitis (NASH) and replicon RNA vaccines.

Following completion of the merger, Alcobra changed its name to Arcturus Therapeutics Ltd and the combined company commenced trading under the ticker symbol “ARCT.” Their office will remain based out of California.

“The evolution of Arcturus Therapeutics continues as we embark on a new chapter for the company as a publicly-traded entity with confidence and optimism,” said Joseph Payne, president and chief executive officer of Arcturus.  “We are now better positioned to accelerate the growth of the company and advance our exciting pipeline of RNA medicines.”